For research use only. Not for therapeutic Use.
Ulenistamab（Cat No.:I042129）is an investigational monoclonal antibody designed to target and block the LAG-3 (Lymphocyte-activation gene 3) receptor, which is expressed on immune cells such as T-cells. LAG-3 acts as an immune checkpoint, inhibiting the immune system’s ability to attack tumors. By inhibiting this pathway, ulenistamab aims to enhance immune responses against cancer cells. It is being evaluated in clinical trials for use in various cancers, including melanoma and non-small cell lung cancer. The drug is often studied in combination with other immunotherapies to improve treatment outcomes.
| CAS Number | 2415259-90-2 |
| Purity | ≥95% |
